• Sidna Tulledge-Scheitel, Sarah J Bell, Jennifer J Larsen, Dennis M Bierle, Paul Takahashi, Darcie E Moehnke, Molly J Destro Borgen, Donna J Springer, Karen J Reinschmidt, Lori J Baumbach, Jennifer A Matoush, Alexander Heyliger, Sara N Hanson, Raymund R Razonable, and Ravindra Ganesh.
• Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
• J Am Geriatr Soc. 2021 Apr 1; 69 (4): 868-873.

BackgroundResidents of nursing homes and long-term care facilities are at increased risk for severe coronavirus disease-19 (COVID-19) but may not be able to access monoclonal antibody therapies offered at outpatient infusion centers due to frailty and logistical issues. We describe a mobile monoclonal antibody infusion program for patients with COVID-19 in skilled nursing facilities and provide descriptive data on its outcomes.DesignRetrospective cohort study.SettingCollaboration between Mayo Clinic and skilled nursing facilities in Southeast Minnesota was developed to administer anti-spike monoclonal antibodies under the FDA Emergency Use Authorization.ParticipantsSeventy five residents of skilled nursing facilities at high risk of COVID-19 complications.ExposureEmergency use treatment with bamlanivimab and casirivimab-imdevimab.MeasurementsHospitalization and medically attended visits.ResultsThe mobile infusion unit, staffed by Mayo Clinic Infusion Therapy registered nurses and supported by the skilled nursing facility staff, infused anti-spike monoclonal antibodies to 45 of 75 patients (average age, 77.8 years) in December 2020. The infusions occurred at an average of 4.3 days after COVID-19 diagnosis. Fourteen days after infusion, there were no deaths, two emergency department visits, and three hospitalizations, for a combined event rate of 11.1%. There was one reported adverse event.ConclusionThe implementation of a mobile infusion unit embedded in a collaborative process resulted in rapid infusion of monoclonal antibodies to high-risk COVID-19 patients in skilled nursing facilities, who would otherwise be unable to access the novel therapies. The therapies were well tolerated and appear beneficial. Further study is warranted to explore the scalability and efficacy of this program.© 2021 The American Geriatrics Society.

21 keywords...

hide…